476192-40-2

Upstream product

• 476192-38-8 C₂₇H₃₅NO₈S 
• 476189-15-8 4-[[4-(3-aminopropoxy)-phenyl]sulfonyl]tetrahydro-2H-pyran-4-carboxylic acid 1,1-dimethylethyl ester, monohydrochloride 
• 476192-13-9 C₂₄H₃₇NO₈S 
• 476192-12-8 4-[(4-fluorophenyl)sulfonyl]tetrahydro-2H-pyran-4-carboxylic acid, 1,1-dimethylethyl ester 
• 6723-30-4 O-2-tetrahydro-2H-pyranhydroxylamine 
• 476195-43-4 C₂₃H₂₇NO₈S 

Downstream Products

• 476183-18-3 tetrahydro-N-hydroxy-4-[[4-[3-[(4-methoxybenzoyl)-amino]propoxy]phenyl]sulfonyl]-2H-pyran-4-carboxamide 

Relevant academic research and scientific papers

MMP-13 selective alpha-sulfone hydroxamates: Identification of selective P1′ amides

Continuing our interest in designing compounds preferentially potent and selective for MMP-13, we report on a series of hydroxamic acids with a flexible amide P1′ substituents. We identify an amide which spares both MMP-1 and -14, and shows >500 fold selectivity for MMP-13 versus MMP-2 and -8.

Aromatic sulfone hydroxamates and their use as protease inhibitors

This invention is directed to aromatic sulfone hydroxamates (also known as “aromatic sulfone hydroxamic acids”) and salts thereof that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. This invention also is directed to a prevention or treatment method that comprises administering such a compound or salt in an MMP-inhibiting and/or aggrecanase-inhibiting effective amount to an animal, particularly a mammal having (or disposed to having) a pathological condition associated with MMP and/or aggrecanase activity.